Jefferies has upgraded GE HealthCare Technologies’ stock from hold to buy, increasing its price target from $95 to $103 per share, suggesting a potential upside of approximately 24% from its recent closing price. Analyst Matthew Taylor highlighted the company’s renewed emphasis on growth and margin expansion through both organic and inorganic investments. He noted that GE HealthCare holds strong positions in diagnostic imaging, ultrasound, patient care solutions, and pharmaceutical diagnostics, benefiting from favorable market conditions.
Currently, GE HealthCare’s stock trades at about 17 to 18 times its projected 2025 earnings, which is lower than its peers and historical averages. Taylor anticipates that successful execution of new products, combined with positive market developments in China—which represents 12% of sales—could enhance the company’s performance.
Looking ahead, GE HealthCare’s total addressable market is expected to grow from about $90 billion in 2023 to $110 billion by 2028, driven by increased demand and an aging population. Year-to-date, the stock has risen nearly 7%, showing strong momentum following its spin-off from General Electric. Overall, analysts remain optimistic, with 12 of 20 recommending it as a buy or strong buy.
